Quick Takeaways
- Beth C. Seidenberg has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $22,079,911.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Beth C. Seidenberg
- Location
- Westlake Village, CA
- Summary
- The estimated net worth of Beth C. Seidenberg is at least $22,079,911 dollars as of 22 Dec 2025. Beth C. Seidenberg is the Director of Progyny, Inc. and owns shares of Progyny, Inc. (PGNY) stock worth about $8.67M. Beth C. Seidenberg is the Director of Vera Therapeutics, Inc. and owns shares of Vera Therapeutics, Inc. (VERA) stock worth about $6.72M. Beth C. Seidenberg is the Director of Kyverna Therapeutics, Inc. and owns shares of Kyverna Therapeutics, Inc. (KYTX) stock worth about $6.65M. Beth C. Seidenberg is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $45.1K.
- Signature
- By: /s/ Jennifer L. Kercher, as Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Beth C. Seidenberg and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Progyny, Inc. ($8,668,738).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Beth C. Seidenberg
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| PGNY | Progyny, Inc. | Director | $8,668,738 | 23 May 2024 | ||
| VERA | Vera Therapeutics, Inc. | Director | $6,715,972 | 14 May 2025 | ||
| KYTX | Kyverna Therapeutics, Inc. | Director | $6,650,121 | +$999,998 | +18% | 18 Dec 2025 |
| ATRA | Atara Biotherapeutics, Inc. | Director | $45,080 | 31 May 2023 | ||
| SLRN | ACELYRIN, Inc. | Director | $0 | 21 May 2025 | ||
| SGMT | Sagimet Biosciences Inc. | Director | 06 Jun 2025 |
Insider Transactions Reported by Beth C. Seidenberg:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.